Urinary MMP-9/UCr association with albumin concentration and albumin-creatinine-ratio in Mexican patients with type 2 diabetes mellitus

Víctor Gildardo Arcos-Sacramento1*, Clara Luz Sampieri1*, Víctor Hugo Sandoval-Lozano1, Rubén Arturo Orozco-Ortega1, Mariel Alejandra Acuña-Hernández1, Jaime Morales-Romero3, Magda Elena Hernández-Hernández2 and Arturo Rodríguez-Hernández3

1 Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México
2 Secretaría de Salud del Estado de Veracruz, Xalapa, Veracruz, México
3 Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 10, Xalapa, Veracruz, México

* These authors contributed equally to this work.

ABSTRACT

Background. Chronic kidney disease is one of the most common complications of type 2 diabetes mellitus (T2DM), causing an increased risk of cardiovascular morbidity and mortality. Matrix metalloproteinase (MMP) activity has been proposed as useful biomarker for diabetic renal and vascular complications.

Methods. A cross-sectional study was conducted among T2DM patients who attended a public secondary hospital in Mexico. We performed clinical, biochemical, and microbiological assessments, as well chronic kidney disease diagnosis according to the KDIGO guideline. Urinary MMP-9 was quantified by ELISA and adjusted using urinary creatinine (UCr).

Results. A total of 111 patients were included. Most participants were women (66%). Mean age was 61 ± 10 years and median T2DM duration was estimated at 11 years. Through multivariate analysis, MMP-9/UCr was found to be associated with albumin concentration and albumin to creatinine ratio.

Discussion. Validation of non-invasive biomarkers of chronic kidney disease among T2DM patients is necessary. Here, we demonstrate MMP-9/UCr as a potential biomarker of albumin concentration and albumin to creatinine ratio in Mexican patients with T2DM.

INTRODUCTION

The prevalence in Mexico in 2016 of previously diagnosed type 2 diabetes mellitus (T2DM), and the combined prevalence of overweightness and obesity were 9.4% and 72.5%, respectively (Rojas-Martínez et al., 2018). Chronic kidney disease (CKD) is a common complication of T2DM, which confers an increased risk of cardiovascular morbidity and mortality (Górriz et al., 2019). Although urine albumin concentration is normally used...
to assess kidney disease development and progression among patients with T2DM, high variability of this marker has been observed, as well as insufficient sensitivity and specificity (Norris et al., 2018).

It has been proposed that a molecule involved in the remodeling process during the early pathology of diabetic kidney disease (DKD) would ideally provide the best marker of disease progression (Altemtam, Nahas & Johnson, 2012). An early event of DKD is excessive extracellular matrix (ECM) accumulation, altering the glomerular and tubular basement membranes and mesangial expansion, possibly causing an increased degree of albuminuria, subsequent proteinuria and fibrosis (Morais et al., 2005; Thrailkill, Bunn & Fowlkes, 2009). Recently, urinary matrix metalloproteinase (MMP) activity has been proposed as a sensitive, non-invasive, and clinically useful biomarker for diabetic renal and vascular complications; however, larger scale studies are necessary in order to confirm their utility (Zheng et al., 2012). Matrix metalloproteinase 9 (MMP-9), also known as gelatinase B, is a multidomain zinc enzyme released mainly by inflammatory cells (Bojic et al., 2015; Zhao et al., 2017). MMP-9 activity is closely regulated on multiple levels, including inhibition by regulatory proteins, such as tissue inhibitors of matrix metalloproteinases (TIMP) (Arpino, Brock & Gill, 2015). In addition to extracellular matrix remodeling, MMP-9 regulates the activity of essential and multiple chemokines, cytokines, receptors, growth factors and cell adhesion molecules to induce tubular endothelial-mesenchymal transition, tubulointerstitial fibrosis and inflammation (Vandooren, Van den Steen & Opdenakker, 2013; Zhao et al., 2013; Zhao et al., 2017).

Liquid chromatography-tandem mass spectrometry analysis has revealed the presence of several collagen peptides in urine from T2DM patients, according to the albumin to creatinine ratio (ACR). Moreover, 48 proteases have potentially been involved in the generation of the most important peptides, including MMP-9 (Brondani et al., 2020). In 24-h urine collection, MMP-8 and MMP-9 activity has been shown to be elevated in accordance with the stage of diabetic nephropathy in T2DM patients, compared to healthy age-matched controls (Van der Zijl et al., 2010). In a previous study, we found an association between renal impairment and the presence of urinary MMP-9 in T2DM (García-Tejeda et al., 2018). In the Mmp-9 gene knockout diabetic mouse model, nephropathic changes such as hypertrophy, increased albuminuria and thickening of the glomerular basement membrane are significantly attenuated (Li et al., 2014). Here, we investigated the possible association between urinary MMP-9 adjusted by urinary creatinine (UCr) and albumin concentration and ACR in Mexican T2DM patients with a diagnosis of CKD.

**METHODS**

**Design and study population**

A cross-sectional study was conducted (November 2016- March 2017) among T2DM patients that were treated in the public second-level unit “Clinica Hospital del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado 25 A 300 400” in Xalapa, Veracruz, Mexico. Criteria for inclusion in the study: ≥18 years of age and meet the clinical requirements to estimate the glomerular filtration rate glomerular filtration rate (GFR),
according to the KDIGO guideline (Kidney Disease Improving Global Outcomes (KDIGO), CKD Work Group, 2012). Conditions that could affect pre-analytical requirements, as well as levels of MMP-9, were controlled, and subjects presenting menstruation, hematuria, presence of sperm in urine (Hirsch et al., 1992), antibiotic treatment, anuria, liver cirrhosis, rheumatoid arthritis, chronic obstructive pulmonary disease, autoimmune disorder and cancer were excluded, as well as those who had had intercourse or exercised vigorously in the 72 h preceding the clinical sampling. The GFR and ACR were each estimated twice, presenting with the second estimation in each case performed some 3 months after the first. Subjects who did not coincide in terms of GFR and ACR categories were excluded.

**Sampling of subjects**

To randomly select subjects, sampling was conducted as previously described in (Hernández-Hernández et al., 2017; García-Tejeda et al., 2018). A convenient size sample was defined as at least 100 participants. To achieve this sample size, a sample frame was defined as at least 290 participants, considering the response and inclusion rates seen in previous studies (Hernández-Hernández et al., 2017; García-Tejeda et al., 2018).

**Ethics**

The research protocol was approved by the investigation committee of the “Clínica Hospital del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado 25 A 300 400” (Register No. 001/073/0230). This study was conducted according to the principles of the Declaration of Helsinki and included subjects signed an informed consent.

**Clinical, biochemical, and microbiological assessments**

Blood samples collection, urine specimens collection, analysis of aerobic bacterial cultures using Cystine-Lactose-Electrolyte Deficient (CLED), anthropometric and vital signs were recorded as previously described in (Hernández-Hernández et al., 2017; García-Tejeda et al., 2018). Glucose, triglycerides, cholesterol, urea and ureic nitrogen were determined in the serum (Cobas C311 Roche). Urine creatinine, urine albumin and seric creatinine were determined using the Jaffé alkaline picrate method (Cobas C311 Roche). Analysis of morning midstream urine specimens were using Combur 10 Test M reagent strips (Cobas U411 Roche). A microscopic examination of urinary sediment was done using Sternheimer-Malbin stain, where 15 fields were analyzed at 40X.

**MMP-9 quantification**

Aliquots of urine samples were centrifuged and stored as previously described in (Hernández-Hernández et al., 2017; García-Tejeda et al., 2018). Human active MMP-9 (82 kDa) and proactive MMP-9 (92 kDa) were measured in urine using a commercially available enzyme-linked immunosorbent assay kit (DMP900 Quantikine; R&D systems, Minneapolis, MN, USA). Each sample, standard curve and controls were assayed following the instructions of the supplier. Blind analysis of the samples was conducted. According to the supplier, the ELISA kit we employed has a sensitivity of 0.156 ng/mL. Intra and inter-assay coefficients of variation were previously established at 5.9% and 7.9%, respectively (García-Tejeda et al., 2018). MMP-9 levels were adjusted by UCr.
Variables
The T2DM was defined as previous medical diagnosis, which was verified in the medical records. The GFR was estimated using sex-specific CKD Epi equations based on serum creatinine (Kidney Disease Improving Global Outcomes (KDIGO), CKD Work Group, 2012). Urine ACR categories were according to the KDIGO guideline (Kidney Disease Improving Global Outcomes (KDIGO), CKD Work Group, 2012). Subjects were classified as “No CKD” or “With CKD”. No CKD: GFR \(\geq 60\) mL/min/1.73 m\(^2\) (GFR categories G1 and G2) and ACR A1 (normal to mildly increased) present for >3 months, while “With CKD”: GFR \(\leq 59\) mL/min/1.73 m\(^2\) and ACR A1, A2 (moderately increased) or A3 (severely increased) or with GFR \(\geq 60\) mL/min/1.73 m\(^2\) and ACR A2 or A3 present for >3 months. Urinary tract infection (UTI) for women and men were according the SIGN guideline (Scottish Intercollegiate Guidelines Network, 2013). Vigorous exercise was defined as practicing athletics, tennis, swimming, or soccer.

Statistical analysis
Categorical variables were summarized using absolute frequencies and percentages. Continuous variables of non-normal distribution were expressed through medians and the interquartile range. Correlation analysis was conducted using the Spearman’s rank correlation. Multivariate analysis was performed in order to identify the association between the independent variable, MMP-9/Ucr and the dependent variables, albumin concentration and ACR. Three models were generated for each dependent variable. Regression coefficient and CI95% were calculated by multivariate linear regression. A value of \(p \leq 0.05\) was considered statistically significant. EpiDat version 3.1 and IBM-SPSS Statistics, version 23 were used for analysis.

RESULTS
A total of 292 patients were invited to participate in the study, with signed informed consent obtained from 99% of those invited. Fifty-eight participants were excluded for not meeting the requirements for calculating GFR, antibiotic treatment, anuria, liver cirrhosis, rheumatoid arthritis, or cancer. Subsequently, 75 participants were excluded for having practiced vigorous exercise in the 72 h preceding the clinical sampling (\(n = 1\)), failure to provide clinical samples (\(n = 14\)), hematuria (\(n = 58\)) and sperm in the urine sample (\(n = 2\)). GFR and ACR were estimated in 158 participants and, more than 3 months later, 137 patients returned for a second estimation of GFR and ACR. The study finally comprised a total of 111 patients with GFR and ACR categories in concordance.

Characteristics of the population
Most of the participants were women and their mean age was 61.3 ± 10.3 years, with 31.5% reported having an education level higher than primary (Table 1). The mean duration of T2DM was 11 years. Most of the patients were prescribed oral hypoglycemic and more than half reported having a diagnosis of hypertension. A total of 18% of the participants had been diagnosed with CKD (Table 1). Markers of kidney damage in urine sediment and granular cylinders were observed in one subject with ACR A2. In the rest of the subjects,
|                                | All patients | With CKD | Without CKD | P-value |
|--------------------------------|--------------|----------|-------------|---------|
|                                | n = 111      | n = 20   | n = 91      |         |
| Sex (males), n (%)             | 38 (34.2)    | 6 (30.0) | 32 (35.2)   | 0.66    |
| Age (years), mean ± SD         | 61.3 ± 10.3  | 63.5 ± 10.6 | 60.8 ± 10.2 | 0.30    |
| Education level ≤ primary, n (%)| 35 (31.5)    | 6 (30.0) | 29 (31.9)   | 0.87    |
| Marital status (without partner), n (%) | 39 (35.1)    | 8 (40.0) | 31 (34.1)   | 0.62    |
| Current smoking, n (%)         | 5 (4.5)      | 1 (5.0)  | 4 (4.4)     | 0.99    |
| Current alcoholism, n (%)      | 30 (27.0)    | 4 (20.0) | 26 (28.6)   | 0.43    |
| Diabetes duration (years), median (P₂₅, P₇₅) | 11.0 (6.0, 17.0) | 20.5 (14.3, 25.8) | 10.0 (6.0, 15.0) | <0.001 |
| Taking oral hypoglycemic agents, n (%) | 107 (96.4)   | 18 (90.0) | 89 (97.8)   | 0.15    |
| Taking insulin, n (%)          | 19 (17.1)    | 6 (30.0) | 13 (14.3)   | 0.11    |
| With hypertension, n (%)       | 62 (55.9)    | 12 (60.0) | 50 (54.9)   | 0.68    |
| Urinary tract infection, n (%) | 8 (7.2)      | 1 (5.0)  | 7 (7.7)     | 0.99    |
| Body mass index (kg/m²), median (P₂₅, P₇₅) | 27.9 (25.3, 31.3) | 25.7 (24.2, 29.1) | 28.4 (25.5, 31.5) | 0.013 |
| Waist circumference (cm), mean ± SD |             |          |             |         |
| Males                          | 96.8 ± 7.5   | 94.4 ± 7.8 | 97.3 ± 7.5 | 0.40    |
| Females                        | 95.7 ± 9.1   | 92.0 ± 9.4 | 96.6 ± 8.9 | 0.09    |
| SBP (mmHg), median (P₂₅, P₇₅)  | 135 (120, 146) | 137 (127, 148) | 135 (120, 145) | 0.51    |
| DBP (mmHg), median (P₂₅, P₇₅)  | 76 (70, 80)  | 73 (69, 80) | 77 (70, 80) | 0.30    |
| Serum glucose (mg/dL), median (P₂₅, P₇₅) | 155 (118, 211) | 150 (118, 234) | 162 (118, 205) | 0.67    |
| Serum creatinine (mg/dL), median (P₂₅, P₇₅) | 0.69 (0.58, 0.80) | 0.68 (0.52, 1.09) | 0.69 (0.59, 0.80) | 0.86    |
| Urinary creatinine (mg/dL), median (P₂₅, P₇₅) | 57.2 (36.7, 88.3) | 51.1 (30.5, 82.7) | 60.3 (41.6, 90.0) | 0.11    |
| Urinary albumin (mg/dL), median (P₂₅, P₇₅) | 0.30 (0.19, 0.95) | 4.8 (3.2, 11.0) | 0.26 (0.19, 0.48) | <0.001  |
| Urinary ACR (mg/g), median (P₂₅, P₇₅) | 5.5 (3.6, 11.3) | 71.2 (53.4, 270.3) | 5.0 (3.1, 7.3) | <0.001  |
| GFR (mL/min/1.73 m²), median (P₂₅, P₇₅) | 97 (88, 102) | 92 (57, 108) | 98 (89, 102) | 0.20    |
| Total cholesterol (mg/dL), mean ± SD | 189.6 ± 39.8 | 186.2 ± 54.9 | 190.4 ± 36.0 | 0.75    |
| Triglycerides (mg/dL), median (P₂₅, P₇₅) | 162 (126, 220) | 231 (128, 273) | 159 (126, 187) | 0.09    |
| Urea (mg/dL), median (P₂₅, P₇₅) | 28.4 (23.5, 34.4) | 31.2 (25.4, 55.5) | 27.7 (23.3, 33.3) | 0.03    |
| Ureic nitrogen (mg/dL), median (P₂₅, P₇₅) | 13.0 (11.0, 16.0) | 14.5 (12.0, 26.0) | 13.0 (11.0, 16.0) | 0.02    |
| MMP9/urinary creatinine (ng/ug), median (P₂₅, P₇₅) | 0.0 (0.0, 0.00013) | 0.0 (0.0, 0.0011) | 0.0 (0.0, 0.0) | 0.23    |
| CFU/mL³, median (P₂₅, P₇₅) | 0 (0, 8000) | 50 (0, 9350) | 0 (0, 6600) | 0.86    |

**GFR and albuminuria category, n**

| Category | All patients | With CKD | Without CKD | P-value |
|----------|--------------|----------|-------------|---------|
| G1 A1    | 68           | NA       | 68          | NA      |
| G1 A2    | 9            | NA       | 9           | NA      |
| G1 A3    | 2            | 2        | NA          | NA      |
| G2 A1    | 23           | NA       | 23          | NA      |
| G2 A2    | 3            | 3        | NA          | NA      |
| G2 A3    | 1            | 1        | NA          | NA      |

(continued on next page)

*PeerJ 2020, DOI 10.7717/peerj.10474*
no markers of kidney damage were observed. Fasting serum glucose levels were above the expected value for patients with T2DM (70–130 mg/dL) (Table 1). The median value of triglycerides was also above reference values (Table 1).

### Univariate and multivariate analysis

Urinary MMP-9 levels were determined by ELISA, which were adjusted to UCr. Seventy-four percent of samples had not detectable MMP-9 (Table 1). There was a positive correlation, with a correlation coefficient of at least 0.3230 between the MMP-9/UCr value with age, serum glucose, ACR and CFU (Table 2).

Six multivariate models were generated to identify the possible association between urinary MMP-9/UCr and albumin concentration and ACR. Age, body mass index (BMI), waist size, systolic blood pressure, diastolic blood pressure and serum glucose were included in the models (Tables 3 and 4). In unadjusted (n = 101), adjusted (n = 101), and adjusted in participants without UTI (n = 94) models, urinary MMP-9/UCr was the only statistically significant variable in albumin concentration and ACR. BMI also showed a statistically significant association in most of the models. The remaining variables were not found to be significantly associated (Tables 3 and 4).

### DISCUSSION

Through two indicators of CKD, our results show that urinary MMP-9/UCr is associated with albuminuria in patients with T2DM, although detection of MMP-9 was in 26% of the subjects, probably due to the sensitivity of the ELISA. A similar association has been reported by van der Zijl and colleagues between MMP-9 activity and incipient diabetic nephropathy (Van der Zijl et al., 2010). Through an MMP activity assay, van der Zijl and colleagues detected urinary MMP-9 activity in 89% and 74% of increased albuminuria and normal albuminuria patients, respectively. Besides the selection of the technique to determine activity instead of levels, the inclusion criteria employed by van der Zijl and colleagues differed from our study in terms of hematuria, UTI, GFR equation and chronicity. Age, serum glucose and CFU were found to be associated with urinary MMP-9/UCr, which is consistent with the literature (Thrailkill et al., 1999; Morais et al., 2005; Kundu et al., 2013; García-Tejeda et al., 2018).
Table 2  Correlation between MMP-9/Ucr (ng/ug) and general characteristics of participants.

| Characteristic                        | Correlation coefficient | P-value |
|---------------------------------------|-------------------------|---------|
| Age (years)                           | 0.2340                  | 0.0135  |
| Type 2 diabetes mellitus (years)      | 0.1160                  | 0.2240  |
| Body mass index (kg/m²)               | 0.0396                  | 0.6800  |
| Waist size (cm)                       | 0.1190                  | 0.2180  |
| Systolic blood pressure (mm Hg)†††    | 0.0052                  | 0.9570  |
| Diastolic blood pressure (mm Hg)††    | −0.0343                 | 0.7290  |
| Serum glucose (mg/dL)                 | 0.2270                  | 0.0167  |
| Serum creatinine (mg/dL)              | −0.0930                 | 0.3310  |
| Urinary creatinine (mg/dL)            | −0.1520                 | 0.1110  |
| Urinary albumin (mg/dL)               | 0.1750                  | 0.0660  |
| Urinary albumin to creatinine ratio (mg/g) | 0.2300                  | 0.0154  |
| Glomerular filtration rate (mL/min/1.73m²) | −0.1720                 | 0.0702  |
| Total cholesterol (mg/dL)             | −0.0198                 | 0.8360  |
| Triglycerides (mg/dL)                 | 0.0218                  | 0.8200  |
| Urea (mg/dL)                          | 0.1800                  | 0.0592  |
| Ureic nitrogen (mg/dL)                | 0.1780                  | 0.0614  |
| CFU/mL††                            | 0.3230                  | <0.0001 |

Notes.
Correlation analysis was performed using the Spearman method.
CFU, colony forming units; MMP, matrix metalloproteinase; UCr, urinary creatinine.
†Determined in 71 females and in 37 males.
‡‡Determined in 67 females and in 37 males.
***CLED agar.

The pathological mechanism of kidney fibrosis involves a series of complex molecular events that produce an excess of ECM deposition. In response to noxious stimuli, renal cells secrete pro-inflammatory and pro-fibrotic molecules that promote the recruitment of inflammatory cells. This inflammatory state can lead to the epithelial-mesenchymal transition (EMT), thus contributing to the progression of fibrosis (Garcia-Fernandez et al., 2020). Studies have shown that MMP upregulation promotes fibrosis, possibly by interaction with overexpressed TIMPs or as a result of the capacity of degradation of ECM by MMP, the degradative products of which can induce EMT (Garcia-Fernandez et al., 2020). The ECM is a versatile and dynamic compartment that harbors cryptic biological functions that can be activated by proteolysis (Visse & Nagase, 2003), as well as being involved in modulating cell proliferation, migration, differentiation and apoptosis (Sato & Yanagita, 2017).

Type IV collagen is the principal component of the glomerular basement membrane and mesangial matrix. Excretion of type IV collagen in urinary samples has been postulated as an indication of matrix turnover in diseased kidneys (Tomino et al., 2001). Since MMP-9 is involved in the degradation of type IV collagen, changes in its expression or activity might reflect early renal damage in T2DM, prior to any increased level of albuminuria (Van der Zijl et al., 2010). MMP-9 has been associated with vascular kidney damage by diverse pathological mechanisms, including matrix deposition, kidney fibrosis, EMT, arterial...
Table 3  Factors associated with albuminuria in participants with type 2 diabetes mellitus.

| Model (not adjusted: n=101) | Regression coefficient | Partial correlation |
|-----------------------------|------------------------|---------------------|
|                            | B          | CI 95%  | Beta  | P-value  |                      |
| MMP-9/Urinary creatinine (ng/ug) | 165.08    | 19.18, 311.98 | 0.23  | 0.0270  | 0.2280               |
| Urinary creatinine (mg/dL)  | −0.001    | −0.02, 0.02 | −0.01 | 0.9220  | −0.0100              |
| Age (years)                | −0.04     | −0.16, 0.08 | −0.08 | 0.4920  | −0.0720              |
| Body mass index (kg/m²)    | −0.31     | −0.73, −0.12 | −0.22 | 0.1550  | −0.1480              |
| Waist size (cm)            | −0.01     | −0.19, 0.17 | −0.01 | 0.9460  | −0.0070              |
| Systolic blood pressure (mm Hg) | 0.04     | −0.02, 0.11 | 0.15  | 0.1830  | 0.1390               |
| Diastolic blood pressure (mm Hg) | −0.03   | −0.16, 0.09 | −0.06 | 0.6080  | −0.0540              |
| Serum glucose (mg/dL)      | −0.01     | −0.02, 0.01 | −0.06 | 0.5650  | −0.0600              |

Model 2 (adjusted: n=101)

| Model (adjusted: n=101) | Regression coefficient | Partial correlation |
|------------------------|------------------------|---------------------|
| MMP-9/ Urinary creatinine (ng/ug) | 160.46    | 24.73, 296.20 | 0.23  | 0.0210  | 0.2310               |
| Body mass index (kg/m²) | −0.31     | −0.58, −0.05 | −0.22 | 0.0220  | −0.2290              |

Model 3 (adjusted in participants without UTI: n=94)

| Model (adjusted in participants without UTI: n=94) | Regression coefficient | Partial correlation |
|---------------------------------------------------|------------------------|---------------------|
| MMP-9/Urinary creatinine (ng/ug)                  | 383.25     | 146.30, 620.19 | 0.31  | 0.0020  | 0.3190               |
| Body mass index (kg/m²)                           | −0.30      | −0.58, −0.02 | −0.21 | 0.0330  | −0.2210              |

Notes.

Dependent variable: urinary albumin (mg/dL). B, non-standardized coefficient. CI 95%, 95% confidence interval for B. Beta, standardized coefficient. MMP, matrix metalloproteinases. UTI, urinary tract infection.

Model 1: corrected square R²: 0.04; P-value = 0.16; inclusion method of the variables: Enter. Ten participants were excluded for lack of blood pressure or waist size data.

Model 2: corrected square R²: 0.08; P-value = 0.007; inclusion method of the variables: Forward. Model adjusted for the following excluded variables (if P-value > 0.05); urinary creatinine (mg/dL), age (years), waist size (cm), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg) and serum glucose (mg/dL). Ten participants were excluded for lack of blood pressure or waist size data.

Model 3: corrected square R²: 0.13; P-value = 0.001; inclusion method of the variables: Forward. Model adjusted for the following excluded variables (if P-value > 0.05); urinary creatinine (mg/dL), age (years), waist size (cm), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg) and serum glucose (mg/dL).

stiffening, vascular calcification, and atherogenesis (Provenzano et al., 2020). MMP-9 has been proposed as a potential therapeutic target to prevent kidney fibrosis in CKD (Zhao et al., 2013).

The EMT is characterized by the loss of epithelial markers such as cytokeratin and E-cadherin, and by nuclear translocation of β-catenin accompanied by expression of mesenchymal markers such as vimentin and α-smooth muscle actin (Tanabe et al., 2020). In patients with T2DM, elevated plasma levels of TGF-β1, CXCL-16 and angiopoietin-2 have been shown as independent predictors of albuminuria and these molecular markers can improve renal risk models beyond established clinical risk factors (Scurt et al., 2019).

Through the direct inhibition of Mmp-9 using a neutralizing antibody in a murine model of unilateral ureteral obstruction, Tan et al. (2013) have suggested a potential mechanism underlying the contribution of Mmp-9 to kidney fibrosis: (1) Mmp-9 cleaves osteopontin; (2) osteopontin plays a key role in macrophage recruitment; (3) infiltration of macrophages; (4) tubular cell EMT and (5) kidney fibrosis. Moreover, Mmp-9 can be upregulated by TGF-β1 in mouse renal peritubular endothelial cells, causing endothelial–mesenchymal transition (Zhao et al., 2017).

No association was found between urinary MMP-9/UCr and BMI. Among reproductive-aged women, a positive correlation has been demonstrated between some serum MMPs,
Table 4  Factors associated with urinary albumin to creatinine ratio in participants with type 2 diabetes mellitus.

| Model 1 (not adjusted: n=101) | Regression coefficient | Partial correlation |
|-------------------------------|------------------------|---------------------|
| | B | CI 95% | Beta | P-value | B | CI 95% | Beta | P-value |
| MMP-9/Urinary creatinine (ng/ug) | 4319.96 | 404.66, 8235.26 | 0.22 | 0.0310 | 0.2230 |
| Urinary creatinine (mg/dL) | -0.37 | -0.94, 0.20 | -0.13 | 0.1980 | -0.1340 |
| Age (years) | -0.83 | -3.96, 2.25 | -0.06 | 0.5920 | -0.0560 |
| Body mass index (kg/m²) | -13.61 | -25.01, -2.20 | -0.36 | 0.0200 | -0.1340 |
| Waist size (cm) | 3.03 | -1.80, 7.86 | 0.19 | 0.2150 | 0.1290 |
| Systolic blood pressure (mm Hg) | 0.46 | -1.29, 2.21 | 0.06 | 0.6050 | 0.0540 |
| Diastolic blood pressure (mm Hg) | -0.06 | -3.42, 3.29 | -0.005 | 0.9700 | -0.0040 |
| Serum glucose (mg/dL) | -0.17 | -0.59, 0.25 | -0.09 | 0.4220 | -0.0840 |

Model 2 (adjusted: n=101)

| Model 2 (adjusted: n=101) | Regression coefficient | Partial correlation |
|-------------------------------|------------------------|---------------------|
| | B | CI 95% | Beta | P-value | B | CI 95% | Beta | P-value |
| MMP-9/Urinary creatinine (ng/ug) | 4476.39 | 798.80, 8153.99 | 0.23 | 0.0180 | 0.2370 |
| Body mass index (kg/m²) | -8.45 | -15.62, -1.29 | -0.23 | 0.0210 | -0.2300 |

Model 3 (adjusted in participants without UTI: n=94)

| Model 3 (adjusted in participants without UTI: n=94) | Regression coefficient | Partial correlation |
|-------------------------------|------------------------|---------------------|
| | B | CI 95% | Beta | P-value | B | CI 95% | Beta | P-value |
| MMP-9/Urinary creatinine (ng/ug) | 8810.32 | 2373.36, 15247.27 | 0.27 | 0.0080 | 0.2740 |
| Body mass index (kg/m²) | -8.57 | -16.07, -1.06 | -0.22 | 0.0260 | -0.2310 |

Notes.

Dependent variable: urinary albumin to creatinine ratio (mg/g).

B, non-standardized coefficient. CI 95%, 95 % confidence interval for B. Beta, standardized coefficient. MMP, matrix metalloproteinases. UTI, urinary tract infection.

Model 1: corrected square $R^2$: 0.06; P-value = 0.08; inclusion method of the variables: Enter. Ten participants were excluded for lack of blood pressure or waist size data.

Model 2: corrected square $R^2$: 0.08; P-value = 0.006; inclusion method of the variables: Forward. Model adjusted for the following excluded variables (if P-value > 0.05); urinary creatinine (mg/dL), age (years), waist size (cm), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg) and serum glucose (mg/dL). Ten participants were excluded for lack of blood pressure or waist size data.

Model 3: corrected square $R^2$: 0.11; P-value = 0.002; inclusion method of the variables: Forward. Model adjusted for the following excluded variables (if P-value > 0.05); urinary creatinine (mg/dL), age (years), waist size (cm), systolic blood pressure (mm Hg), diastolic blood pressure (mm Hg) and serum glucose (mg/dL).

including MMP-9, and BMI, as well as significantly higher concentrations of MMPs being found in obese subjects, compared to patients of normal BMI (Grzechocińska et al., 2019). Plasma gelatinase MMP-9 activity has been reported as being significantly higher in obese compared to non-obese patients, which could be reversed by bariatric surgery (García-Prieto et al., 2019). A novel function for MMPs as modulators of adipogenesis has been reported as a consequence of abnormal ECM metabolism (Derou, 2008). In animal models, lipid deposition is found in tubular and glomerular portions of the kidneys, the major sites of diabetic nephropathy lesions (Thongnak, Pongchaidecha & Lungkaphin, 2020).

Given the pathophysiological processes that encompass DKD, such as hyperfiltration and pro-fibrotic, pro-inflammatory and angiogenic processes, it has been challenged whether albuminuria, or any other single biomarker, is individually capable of accurately forecasting the development and progression of renal damage in T2DM (Norris et al., 2018). Moreover, a consensus classification of type 1 and type 2 diabetic nephropathies, that covers the entire kidney, states that the early event is injury to the tubules and vessels, rather than glomerular lesions (Tervaert et al., 2010). In our population with G1 and G2 GFR categories, the existence of extra glomerular lesions, and even hyperfiltration, is therefore possible.
The negative association found between BMI with albumin concentration and ACR is conflictive. Higher BMI has been positively correlated with higher ACR and an increased risk of major renal events in patients with T2DM (Mohammed et al., 2018). Although, Raikou & Gavriil (2019) found that obesity is not a significant risk factor for an increased degree of albuminuria in hypertensive patients with a poor estimated GFR rate, when both diabetes mellitus and a low eGFR value act as confounders.

This study presents some limitations related to the sensitivity of the ELISA kit, and the absence of MMP-9 found in urinary samples might be questionable. Another limitation of this study is the inclusion of patients that received renin-angiotensin system drugs, given their effect on the expression of some MMPs (Lods, 2003). The strengths of this study are the well-defined population and robust statistical analysis. We consider this study is particularly relevant, since CKD prevalence and mortality rate have doubled in Mexico over the last 20 years (Dávila-Torres, González-Izquierdo & Barrera-Cruz, 2015; Salinas Martínez et al., 2020). For this reason, larger-scale studies are required in the Mexican population in order to determine the predictive values of urinary MMP-9/UCr, including sensitivity, positive predictive value, negative predictive value, probability ratio for positive test, probability ratio for negative test and area under the ROC curve. Ideally, these studies should include other kidney disease in order to demonstrate specificity.

CONCLUSIONS

Non-invasive biomarkers of urine are required to assess DKD development and progression. The present study demonstrated that MMP-9/UCr correlated positively with urine albumin concentration and ACR in Mexican patients with T2DM. We propose MMP-9/UCr as a possible early biomarker of CKD in T2DM patients.

ACKNOWLEDGEMENTS

The authors are grateful to the subjects who participated in this study and to the anonymous reviewers of this journal for their suggestions. Thanks go to QFB Soledad Enríquez Hernández for the clinical laboratory facilities and Dr. Héctor Hernández Gutiérrez for the facilities provided to carry out this study. Dr. Samuel Treviño Mora and MC José Ángel Flores for the training for the microscopic examination of urinary sediment determination at the Benemérita Universidad de Puebla and Dr. Héctor Gabriel Acosta Mesa for the facilities with the microscope at Universidad Veracruzana.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by Instituto de Salud Pública (awarded to Clara Luz Sampieri and Jaime Morales-Romero). A postgraduate degree scholarship was awarded to Víctor Gildardo Arcos-Sacramento (590202, from Consejo Nacional de Ciencia y Tecnología, CONACyT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Grant Disclosures
The following grant information was disclosed by the authors:
Instituto de Salud Pública.
Consejo Nacional de Ciencia y Tecnología, CONACyT: 590202.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Víctor Gildardo Arcos-Sacramento, Rubén Arturo Orozco-Ortega, Mariel Alejandra Acuña-Hernández and Arturo Rodríguez-Hernández conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
• Clara Luz Sampieri and Víctor Hugo Sandoval-Lozano conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
• Jaime Morales-Romero and Magda Elena Hernández-Hernández conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Human Ethics
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
Investigation Committee of the Clínica Hospital del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado 25 A 300 400 and Instituto de Salud Pública approved this research (Register No. 001/073/0230).

Data Availability
The following information was supplied regarding data availability:
The raw data are available in Supplemental File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.10474#supplemental-information.

REFERENCES
Altemtam N, Nahas ME, Johnson T. 2012. Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression. Nephron Extra 2:219–232 DOI 10.1159/000339645.

Arpino V, Brock M, Gill SE. 2015. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biology: Journal of the International Society for Matrix Biology 44–46:247–254 DOI 10.1016/j.matbio.2015.03.005.

Bojic S, Kotur-Stevuljevic J, Kalezic N, Stevanovic P, Jelic-Ivanovic Z, Bilanovic D, Memon L, Damnjanovic M, Kalaba Z, Simic-Ogrizovic S. 2015. Diagnostic value
of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis-associated acute kidney injury. *The Tohoku Journal of Experimental Medicine* 237:103–109 DOI 10.1620/tjem.237.103.

Brondani LDA, Soares AA, Recamonde-Mendoza M, Dall’Agnol A, Camargo JL, Monteiro KM, Silveiro SP. 2020. Urinary peptidomics and bioinformatics for the detection of diabetic kidney disease. *Scientific Reports* 10:1242 DOI 10.1038/s41598-020-58067-7.

Dávila-Torres J, González-Izquierdo JDJ, Barrera-Cruz A. 2015. Panorama de la obesidad en México. *Revista Médica del Instituto Mexicano del Seguro Social* 53(2):240–249.

Derosa G, Ferrari I, D’Angelo A, Tinelli C, Salvadeo SAT, Ciccarelli I, Piccinni MN, Gravina A, Ramonetti F, Maffioli P, Cicero AFG. 2008. Matrix metalloproteinase-2 and -9 levels in obese patients. *Endothelium: Journal of Endothelial Cell Research* 15:219–224 DOI 10.1080/10623320802228815.

Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM, Vergara A, Orbe J, Soler MJ. 2020. Matrix metalloproteinases in diabetic kidney disease. *Journal of Clinical Medicine* 92:472 DOI 10.3390/jcm9020472.

García-Prieto CF, Gil-Ortega M, Vega-Martín E, Ramiro-Cortijo D, Martín-Ramos M, Bordiú E, Sanchez-Pernaute A, Torres A, Aránguez I, Fernández-Alfonso M, Rubio MA, Somoza B. 2019. Beneficial effect of bariatric surgery on abnormal MMP-9 and AMPK activities: potential markers of obesity-related CV risk. *Frontiers in Physiology* 10:553 DOI 10.3389/fphys.2019.00553.

García-Tejeda AU, Sampieri CL, Suárez-Torres I, Morales-Romero J, Demeneghi-Marini VP. 2018. Association of urinary activity of MMP-9 with renal impairment in Mexican patients with type 2 diabetes mellitus. *PeerJ* 6:e6067 DOI 10.7717/peerj.6067.

Górriz JL, Cos Claramunt FX, Duque N, Matali A. 2019. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care. *Primary Care Diabetes* 13:485–494 DOI 10.1016/j.pcd.2019.07.001.

Grzechocińska B, Dąbrowski FA, Sierdzinski J, Cyganek A, Wielgoś M. 2019. The association between serum metalloproteinase concentration, obesity, and hormone levels in reproductive-aged women. *Endokrynologia Polska* 70:49–56 DOI 10.5603/EP.a2018.0067.

Hernández-Hernández ME, Morales-Romero J, Sampieri CL, Luna Lozano DJ, Valencia Lezama IDC, Muñoz Contreras MJ, Rodríguez Hernández A. 2017. Association of urinary activity of MMP-2 with microalbuminuria in an isolated sample of subjects living in high altitude rural locations in México. *High Altitude Medicine & Biology* 18:209–218 DOI 10.1089/ham.2016.0144.

Hirsch IB, Farkas-Hirsch R, Herbst JS, Skyler JS. 1992. The effect of ejaculation on albumin excretion rate. *Journal of Diabetes and its Complications* 6:163–165 DOI 10.1016/1056-8727(92)90031-F.
Kidney Disease: Improving Global Outcomes (KDIGO). CKD Work Group. KDIGO. 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International Supplements* 3:1–150.

Kundu S, Pushpakumar SB, Tyagi A, Coley D, Sen U. 2013. Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9. *American Journal of Physiology* 304:E1365–E1378 DOI 10.1152/ajpendo.00604.2012.

Li SY, Huang PH, Yang AH, Targn DC, Yang WC, Lin CC, Chen JW, Schmid-Schönbein G, Lin S-J. 2014. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. *Kidney International* 86:358–369 DOI 10.1038/ki.2014.67.

Lods N. 2003. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. *Journal of the American Society of Nephrology* 14:2861–2872 DOI 10.1097/01.ASN.0000092789.67966.5C.

Mohammed K, Chalmers J, Herrington W, Li Q, Mancia G, Marre M, Poulter N, Rodgers A, Williams B, Perkovic V, Coresh J, Woodward M. 2018. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. *Nutrition & Diabetes* 8:7 DOI 10.1038/s41387-017-0012-y.

Morais C, Westhuyzen J, Pat B, Gobe G, Healy H. 2005. High ambient glucose is effect neutral on cell death and proliferation in human proximal tubular epithelial cells. *American Journal of Physiology. Renal Physiology* 289:F401–F409 DOI 10.1152/ajprenal.00408.2004.

Norris KC, Smoyer KE, Rolland C, Van der Vaart J, Grubb EB. 2018. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. *BMC Nephrology* 19:36 DOI 10.1186/s12882-018-0821-9.

Provenzano M, Andreucci M, Garofalo C, Faga T, Michael A, Ielapi N, Grande R, Sapienza P, De Franciscis S, Mastoroberto P, Serra R. 2020. The association of matrix metalloproteinases with chronic kidney disease and peripheral vascular disease: a light at the end of the tunnel? *Biomolecules* 10(1):154 DOI 10.3390/biom10010154.

Raikou VD, Gavriil S. 2019. Body-mass index and the risk of albuminuria in hypertensive patients with a poor estimated glomerular filtration rate and the potential role of diabetes mellitus. *Diabetes & Metabolic Syndrome* 13:1041–1046 DOI 10.1016/j.dxs.2019.01.017.

Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. 2018. Prevalence of previously diagnosed diabetes mellitus in Mexico. *Salud Publica De Mexico* 60:224–232 DOI 10.21149/8566.

Salinas Martínez AM, Cordero Franco HF, Estradade León DB, Medina Franco GE, Guzmán de la Garza FJ, Núñez Rocha GM. 2020. Estimating and differentiating maternal feeding practices in a country ranked first in childhood obesity. *Public Health Nutrition* 23:620–630 DOI 10.1017/S1368980019003173.
Sato Y, Yanagita M. 2017. Resident fibroblasts in the kidney: a major driver of fibrosis and inflammation. *Inflammation and Regeneration* 37:17 DOI 10.1186/s41232-017-0048-3.

Scottish Intercollegiate Guidelines Network. 2013. Management of suspected bacterial urinary tract infection in adults: a national clinical guideline. Edinburgh: Sign.

Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, Chatzikyrkou C. ROADMAP Steering Committee. 2019. Systemic inflammation precedes microalbuminuria in diabetes. *Kidney International Reports* 4:1373–1386 DOI 10.1016/j.ekir.2019.06.005.

Tan TK, Zheng G, Hsu T-T, Lee SR, Zhang J, Zhao Y, Tian X, Wang Y, Wang YM, Cao Q, Wang Y, Lee VWS, Wang C, Zheng D, Alexander SI, Thompson E, Harris DCH. 2013. Matrix metalloproteinase-9 of tubular and macrophage origin contributes to the pathogenesis of renal fibrosis via macrophage recruitment through osteopontin cleavage. *Laboratory Investigation; a Journal of Technical Methods and Pathology* 93:434–449 DOI 10.1038/labinvest.2013.3.

Tanabe S, Quader S, Cabral H, Ono R. 2020. Interplay of EMT and CSC in cancer and the potential therapeutic strategies. *Frontiers in Pharmacology* 11:904 DOI 10.3389/fphar.2020.00904.

Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, De Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA. 2010. Pathologic classification of diabetic nephropathy. *Journal of the American Society of Nephrology* 21:556–563 DOI 10.1681/ASN.2010010010.

Thongnak L, Pongchaidecha A, Lungkaphin A. 2020. Renal lipid metabolism and lipotoxicity in diabetes. *The American Journal of the Medical Sciences* 359:84–99 DOI 10.1016/j.amjms.2019.11.004.

Thrailkill KM, Bunn RC, Fowlkes JL. 2009. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. *Endocrine* 35:1–10 DOI 10.1007/s12020-008-9114-6.

Thrailkill KM, Kumar S, Rosenberg CK, Auten KJ, Fowlkes JL. 1999. Characterization of matrix metalloproteinases in human urine: alterations during adolescence. *Pediatric Nephrology* 13:223–229 DOI 10.1007/s004670050597.

Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, Wang LN, Chen H, Lai K, Tan SY, Kim MJ. 2001. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. *Journal of Clinical Laboratory Analysis* 15:188–192 DOI 10.1002/jcla.1026.

Vandooren J, Van den Steen PE, Opdenakker G. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. *Critical Reviews in Biochemistry and Molecular Biology* 48:222–272 DOI 10.3109/10409238.2013.770819.

Van der Zijl NJ, Hanemaaier R, Tushuizen ME, Schindhelm RK, Boerop J, Rustemeijer C, Bilo HJ, Verheijen JH, Diamant M. 2010. Urinary matrix metalloproteinase-8
and α9 activities in type 2 diabetic subjects: a marker of incipient diabetic nephropathy? *Clinical Biochemistry* 43:635–639 DOI 10.1016/j.clinbiochem.2010.02.006.

Visse R, Nagase H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circulation Research* 92:827–839 DOI 10.1161/01.RES.0000070112.80711.3D.

Zhao H, Dong Y, Tian X, Tan TK, Liu Z, Zhao Y, Zhang Y, Harris DC, Zheng G. 2013. Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. *World Journal of Nephrology* 2:84–89 DOI 10.5527/wjn.v2.i3.84.

Zhao Y, Qiao X, Tan TK, Zhao H, Zhang Y, Liu L, Zhang J, Wang L, Cao Q, Wang Y, Wang Y, Wang YM, Lee VWS, Alexander SI, Harris DCH, Zheng G. 2017. Matrix metalloproteinase 9-dependent Notch signaling contributes to kidney fibrosis through peritubular endothelial-mesenchymal transition. *Nephrology, Dialysis, Transplantation* 32:781–791 DOI 10.1093/ndt/gfw308.

Zheng M, Lv L-L, Cao Y-H, Zhang J-D, Wu M, Ma K-L, Phillips AO, Liu B-C. 2012. Urinary mRNA markers of epithelial–mesenchymal transition correlate with progression of diabetic nephropathy. *Clinical Endocrinology* 76:657–664 DOI 10.1111/j.1365-2265.2011.04192.x.